AIF |
Apoptosis-inducing factor |
aSMase |
Acid sphingomyelinase |
ATF6 |
Activating transcription factor 6 |
ATP |
Adenosine triphosphate |
BER |
Base excision repair |
CDDP |
Cisplatin |
CHOP |
C/EMP homologous protein |
CP |
Carboplatin |
CRT |
Calreticulin |
CTR1 |
High affinity copper uptake protein 1 |
Cyt C
|
Cytochrome C
|
DAMP |
Damage-associated molecular patterns |
DC |
Dendritic cell |
DISC |
Death-inducing signalling complex |
DSB |
Double strand breaks |
ER |
Endoplasmic reticulum |
ERCC1 |
Cross-complementation group 1 |
FasR |
Fas receptor |
FDA |
US Food and Drug Administration |
FOLFOX |
5-fluorouracil, leucovorin, oxaliplatin drug combination |
GEMOX |
Gemcitabine, oxaliplatin drug combination |
GSH |
Glutathione |
HCC |
Hepatocellular carcinoma |
HMGB1 |
High-mobility group box 1 |
HR |
Homologous recombination |
HSOS |
Hepatic sinusoidal obstruction syndrome |
IAP |
Inhibitors of apoptosis proteins |
ICD |
Immunogenic cell death |
ICL |
Interstrand crosslink |
IRE1α |
Inositol-requiring protein 1α |
IROX |
Irinotecan, oxaliplatin drug combination |
miRNA |
microRNA |
MMR |
Mismatch repair |
MRP |
Multidrug resistance proteins |
mtDNA |
Mitochondrial DNA |
nDNA |
Nuclear DNA |
NPM1 |
Nucleophosmin |
Nrf2 |
NF-E2-related factor 2 |
OCT |
Organic cation transporter |
OIPN |
Oxaliplatin-induced peripheral neuropathy |
OXP |
Oxaliplatin |
pEIF2α |
Phosphorylated eukaryotic translation factor 2α |
PERK |
Protein kinase RNA-like endoplasmic reticulum kinase |
Pol I |
RNA Polymerase I |
Pt |
Platinum |
Pt |
Platinum |
ROS |
Reactive oxygen species |
rRNA |
Ribosomal RNA |
ssDNA |
Single strand DNA breaks |
SSRP1 |
structure specific recognition protein 1 |
TFIIH |
Transcription factor II H |
TLR4 |
Toll-like receptor 4 |
UBF |
Upstream binding factor |
XPC |
Xeroderma pigmentosum |